Literature DB >> 17339260

Complete response in a patient with colonic mantle cell lymphoma with multiple lymphomatous polyposis treated with combination chemotherapy using anti-CD20 antibody and cladribine.

Takuya Watanabe, Nobuyuki Homma, Norio Ogata, Hiroyuki Saito, Tsutomu Kanefuji, Katsuhiko Hasegawa, Kenji Soga, Koichi Shibasaki, Takeshi Endo, Yoichi Ajioka.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17339260      PMCID： PMC1856801          DOI： 10.1136/gut.2006.114207

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  8 in total

1.  [Anti-CD20 antibody and combination chemotherapy followed by autologous peripheral blood stem cell transplantation after high-dose chemotherapy induced complete remission in a case of multiple lymphomatous polyposis of the gastrointestinal tract].

Authors:  Tomohide Mukogawa; Hisao Fujii; Fumikazu Koyama; Hiroshi Matsumoto; Yu Kojima; Taku Takeuchi; Hideo Yagi; Masanobu Arai; Yoshiyuki Nakajima
Journal:  Nihon Shokakibyo Gakkai Zasshi       Date:  2003-12

2.  Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas.

Authors:  D Decaudin; J Bosq; G Tertian; G Nedellec; A Bennaceur; A M Venuat; C Bayle; P Carde; B Bendahmane; M Hayat; J N Munck
Journal:  J Clin Oncol       Date:  1998-02       Impact factor: 44.544

3.  Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma.

Authors:  Y Yatabe; R Suzuki; K Tobinai; Y Matsuno; R Ichinohasama; M Okamoto; M Yamaguchi; J Tamaru; N Uike; Y Hashimoto; Y Morishima; T Suchi; M Seto; S Nakamura
Journal:  Blood       Date:  2000-04-01       Impact factor: 22.113

4.  Clinicopathologic study of PRAD1/cyclin D1 overexpressing lymphoma with special reference to mantle cell lymphoma. A distinct molecular pathologic entity.

Authors:  Y Yatabe; S Nakamura; M Seto; H Kuroda; Y Kagami; R Suzuki; M Ogura; M Kojima; T Koshikawa; R Ueda; T Suchi
Journal:  Am J Surg Pathol       Date:  1996-09       Impact factor: 6.394

5.  Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).

Authors:  Georg Lenz; Martin Dreyling; Eva Hoster; Bernhard Wörmann; Ulrich Dührsen; Bernd Metzner; Hartmut Eimermacher; Andreas Neubauer; Hannes Wandt; Hjalmar Steinhauer; Sonja Martin; Else Heidemann; Ali Aldaoud; Reza Parwaresch; Joerg Hasford; Michael Unterhalt; Wolfgang Hiddemann
Journal:  J Clin Oncol       Date:  2005-01-24       Impact factor: 44.544

6.  Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network.

Authors:  B S Kahl; W L Longo; J C Eickhoff; J Zehnder; C Jones; J Blank; T McFarland; W Bottner; H Rezazedeh; J Werndli; H H Bailey
Journal:  Ann Oncol       Date:  2006-06-09       Impact factor: 32.976

7.  Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody.

Authors:  T Maeda; Y Yamada; M Tawara; R Yamasaki; Y Yakata; C Tsutsumi; Y Onimaru; S Kamihira; M Tomonaga
Journal:  Int J Hematol       Date:  2001-07       Impact factor: 2.490

Review 8.  Multiple lymphomatous polyposis of the gastrointestinal tract. A clinicopathologically distinctive form of non-Hodgkin's lymphoma of B-cell centrocytic type.

Authors:  D S O'Briain; M J Kennedy; P A Daly; A A O'Brien; W A Tanner; P Rogers; E Lawlor
Journal:  Am J Surg Pathol       Date:  1989-08       Impact factor: 6.394
  8 in total
  2 in total

1.  Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group.

Authors:  David J Inwards; Paul A S Fishkin; David W Hillman; David W Brown; Stephen M Ansell; Paul J Kurtin; Rafael Fonseca; Roscoe F Morton; Michael H Veeder; Thomas E Witzig
Journal:  Cancer       Date:  2008-07-01       Impact factor: 6.860

Review 2.  Rare gastrointestinal lymphomas: The endoscopic investigation.

Authors:  Calogero Vetro; Giacomo Bonanno; Giorgio Giulietti; Alessandra Romano; Concetta Conticello; Annalisa Chiarenza; Paolo Spina; Francesco Coppolino; Rosario Cunsolo; Francesco Di Raimondo
Journal:  World J Gastrointest Endosc       Date:  2015-08-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.